| Nome |
# |
|
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy, file e0feeaa8-6862-44d2-e053-6605fe0a8db0
|
188
|
|
Towards the introduction of the Immunoscore in the classification of malignant tumors, file e0feeaa8-5c17-44d2-e053-6605fe0a8db0
|
184
|
|
Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls, file e0feeaa8-5a5c-44d2-e053-6605fe0a8db0
|
174
|
|
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, file e0feeaa8-8a91-44d2-e053-6605fe0a8db0
|
167
|
|
THE ITALIAN EXPERIENCE ON THE FEASIBILITY AND SAFETY OF IPILIMUMAB THERAPY IN PRETREATED METASTATIC MELANOMA PATIENTS, file e0feeaa8-44d1-44d2-e053-6605fe0a8db0
|
142
|
|
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours, file e0feeaa8-9ff1-44d2-e053-6605fe0a8db0
|
140
|
|
IPILIMUMAB IN PRETREATED METASTATIC UVEAL MELANOMA PATIENTS: SAFETY AND CLINICAL EFFICACY, file e0feeaa8-9eca-44d2-e053-6605fe0a8db0
|
134
|
|
Future perspectives in melanoma research. Meeting report from the “Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011”, file e0feeaa8-ae9c-44d2-e053-6605fe0a8db0
|
128
|
|
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients, file e0feeaa8-6940-44d2-e053-6605fe0a8db0
|
124
|
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010", file e0feeaa8-7c9e-44d2-e053-6605fe0a8db0
|
121
|
|
Implementing liquid biopsies into clinical decision making for cancer immunotherapy, file e0feeaa8-b1f9-44d2-e053-6605fe0a8db0
|
118
|
|
null, file e0feeaa8-4b94-44d2-e053-6605fe0a8db0
|
115
|
|
Predictors of responses to immune checkpoint blockade in advanced melanoma, file e0feeaa8-a1f6-44d2-e053-6605fe0a8db0
|
115
|
|
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme, file e0feeaa8-5a5e-44d2-e053-6605fe0a8db0
|
114
|
|
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma, file e0feeaa8-5298-44d2-e053-6605fe0a8db0
|
113
|
|
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells, file e0feeaa8-ac23-44d2-e053-6605fe0a8db0
|
113
|
|
The role of BRAF V600 mutation in melanoma, file e0feeaa8-7c24-44d2-e053-6605fe0a8db0
|
106
|
|
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy, file e0feeaa8-4cfb-44d2-e053-6605fe0a8db0
|
99
|
|
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients, file e0feeaa8-57f9-44d2-e053-6605fe0a8db0
|
99
|
|
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response, file e0feeaa8-7385-44d2-e053-6605fe0a8db0
|
99
|
|
Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy, file e0feeaa8-8d63-44d2-e053-6605fe0a8db0
|
99
|
|
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients, file e0feeaa8-ae9b-44d2-e053-6605fe0a8db0
|
99
|
|
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies, file e0feeaa8-aa29-44d2-e053-6605fe0a8db0
|
95
|
|
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology, file e0feeaa8-59bd-44d2-e053-6605fe0a8db0
|
94
|
|
Defining the Critical Hurdles in Cancer Immunotherapy, file e0feeaa8-7c26-44d2-e053-6605fe0a8db0
|
91
|
|
null, file e0feeaa8-9a4a-44d2-e053-6605fe0a8db0
|
86
|
|
Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort, file e0feeaa9-972c-44d2-e053-6605fe0a8db0
|
74
|
|
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma, file e0feeaa8-b3e3-44d2-e053-6605fe0a8db0
|
64
|
|
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients, file e0feeaa9-af7d-44d2-e053-6605fe0a8db0
|
64
|
|
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival, file e0feeaa8-6cbc-44d2-e053-6605fe0a8db0
|
61
|
|
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma, file e0feeaa8-aaf5-44d2-e053-6605fe0a8db0
|
56
|
|
The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates, file e0feeaa9-f518-44d2-e053-6605fe0a8db0
|
56
|
|
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial, file e0feeaa9-e0ba-44d2-e053-6605fe0a8db0
|
54
|
|
Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy, file e0feeaa9-cab3-44d2-e053-6605fe0a8db0
|
53
|
|
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, file e0feeaa9-972a-44d2-e053-6605fe0a8db0
|
46
|
|
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT), file e0feeaa8-b1c8-44d2-e053-6605fe0a8db0
|
43
|
|
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013, file e0feeaa9-e0bf-44d2-e053-6605fe0a8db0
|
41
|
|
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients, file e0feeaa8-5464-44d2-e053-6605fe0a8db0
|
37
|
|
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials, file e0feeaa8-aa28-44d2-e053-6605fe0a8db0
|
30
|
|
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme, file e0feeaa5-1009-44d2-e053-6605fe0a8db0
|
27
|
|
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy, file e0feeaab-b69c-44d2-e053-6605fe0a8db0
|
27
|
|
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab, file e0feeaab-ba30-44d2-e053-6605fe0a8db0
|
25
|
|
Immunotherapy of brain metastases: breaking a "dogma", file e0feeaa9-8fee-44d2-e053-6605fe0a8db0
|
23
|
|
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID, file fd7485c6-e63d-4df4-b0cf-d2d9661dcc8c
|
23
|
|
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma, file bb6d5af7-9329-4b82-9270-4dbbbbe3cccf
|
16
|
|
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy, file 5b956718-c7de-46ad-84c1-a6964fd2616b
|
13
|
|
Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach, file e0feeaa9-728d-44d2-e053-6605fe0a8db0
|
13
|
|
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop”, file 6c496e86-513d-4b28-8825-cd0b727f8eca
|
9
|
|
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel, file 2aeb2994-eb76-4ae2-bf77-db11517d883e
|
7
|
|
A novel microRNA signature for the detection of melanoma by liquid biopsy, file a8dd45d0-8f03-4a6a-a067-f917b7755506
|
7
|
|
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy, file e0feeaa8-03a0-44d2-e053-6605fe0a8db0
|
7
|
|
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation, file e0feeaab-b69a-44d2-e053-6605fe0a8db0
|
5
|
|
The cost of unresectable stage III or stage IV melanoma in Italy, file 1c2475f5-59fa-43bd-96fc-5940af9454d2
|
3
|
|
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study), file e0feeaa8-9b7c-44d2-e053-6605fe0a8db0
|
3
|
|
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab, file e0feeaab-ba31-44d2-e053-6605fe0a8db0
|
3
|
|
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?, file 2ea79330-47b5-4614-be53-0c60d694ad75
|
2
|
|
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features, file 45783305-2a15-42cd-b8b8-127c8ec8a32e
|
2
|
|
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases, file cd22717f-88f2-4ff4-bd99-03bc8951c290
|
2
|
|
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy., file e0feeaa4-eaf8-44d2-e053-6605fe0a8db0
|
2
|
|
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis, file e0feeaa8-3e06-44d2-e053-6605fe0a8db0
|
2
|
|
Biomolecular strategies for therapeutic intervention in cancer, file e0feeaa8-440c-44d2-e053-6605fe0a8db0
|
2
|
|
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial, file e0feeaa8-50d7-44d2-e053-6605fe0a8db0
|
2
|
|
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients, file e0feeaa8-9ec6-44d2-e053-6605fe0a8db0
|
2
|
|
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma, file e0feeaa8-aa2a-44d2-e053-6605fe0a8db0
|
2
|
|
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study, file e0feeaa8-aaf2-44d2-e053-6605fe0a8db0
|
2
|
|
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab, file e0feeaa8-aaf9-44d2-e053-6605fe0a8db0
|
2
|
|
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, file e0feeaa8-aafe-44d2-e053-6605fe0a8db0
|
2
|
|
“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014, file e0feeaa8-ab02-44d2-e053-6605fe0a8db0
|
2
|
|
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, file e0feeaa8-ab04-44d2-e053-6605fe0a8db0
|
2
|
|
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study), file e0feeaa8-b0e1-44d2-e053-6605fe0a8db0
|
2
|
|
Nivolumab plus ipilimumab in melanoma brain metastases, file e0feeaab-4c50-44d2-e053-6605fe0a8db0
|
2
|
|
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study, file e0feeaab-c4e2-44d2-e053-6605fe0a8db0
|
2
|
|
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial, file 1ccf50c8-e712-4f4e-b22c-ee56c54c6dce
|
1
|
|
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines, file 49dee18e-2a65-4937-99fd-4598eaba8b1c
|
1
|
|
Immunotherapy for brain metastases and primary brain tumors., file 586ed86d-ec6b-4872-9b7c-71713060601f
|
1
|
|
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy), file e0feeaa4-c866-44d2-e053-6605fe0a8db0
|
1
|
|
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study, file e0feeaa8-42ce-44d2-e053-6605fe0a8db0
|
1
|
|
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study, file e0feeaa8-42cf-44d2-e053-6605fe0a8db0
|
1
|
|
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, file e0feeaa8-4aac-44d2-e053-6605fe0a8db0
|
1
|
|
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy, file e0feeaa8-4b82-44d2-e053-6605fe0a8db0
|
1
|
|
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF(V600)-mutated Metastatic Melanoma, file e0feeaa8-4b84-44d2-e053-6605fe0a8db0
|
1
|
|
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme, file e0feeaa8-50df-44d2-e053-6605fe0a8db0
|
1
|
|
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial, file e0feeaa8-50e5-44d2-e053-6605fe0a8db0
|
1
|
|
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial, file e0feeaa8-52a6-44d2-e053-6605fe0a8db0
|
1
|
|
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010, file e0feeaa8-537b-44d2-e053-6605fe0a8db0
|
1
|
|
Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008., file e0feeaa8-58d9-44d2-e053-6605fe0a8db0
|
1
|
|
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, file e0feeaa8-6575-44d2-e053-6605fe0a8db0
|
1
|
|
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases, file e0feeaa8-67f2-44d2-e053-6605fe0a8db0
|
1
|
|
Epigenetic drugs as immunomodulators for combination therapies in solid tumors, file e0feeaa8-67fc-44d2-e053-6605fe0a8db0
|
1
|
|
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?, file e0feeaa8-6b22-44d2-e053-6605fe0a8db0
|
1
|
|
Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25, file e0feeaa8-6b23-44d2-e053-6605fe0a8db0
|
1
|
|
Erratum: Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25, file e0feeaa8-6b24-44d2-e053-6605fe0a8db0
|
1
|
|
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial, file e0feeaa8-71d7-44d2-e053-6605fe0a8db0
|
1
|
|
Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey, file e0feeaa8-737e-44d2-e053-6605fe0a8db0
|
1
|
|
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial, file e0feeaa8-73d5-44d2-e053-6605fe0a8db0
|
1
|
|
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012, file e0feeaa8-7985-44d2-e053-6605fe0a8db0
|
1
|
|
The biology of cancer testis antigens: putative function, regulation and therapeutic potential, file e0feeaa8-7c25-44d2-e053-6605fe0a8db0
|
1
|
|
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study, file e0feeaa8-8b9c-44d2-e053-6605fe0a8db0
|
1
|
|
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial, file e0feeaa8-8d64-44d2-e053-6605fe0a8db0
|
1
|
|
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial, file e0feeaa8-8d65-44d2-e053-6605fe0a8db0
|
1
|
| Totale |
4.109 |